• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Merck Commits to Veeva Vault CRM

    7/21/25 10:00:00 AM ET
    $MRK
    $VEEV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $MRK alert in real time by email

    Deep application provides foundation for commercial execution

    PLEASANTON, Calif., July 21, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced that Merck (NYSE:MRK), known as MSD outside of the United States and Canada, has committed to Veeva Vault CRM.

    Veeva Systems (PRNewsfoto/Veeva Systems)

    The Vault CRM solution will support Merck as they enter one of the most significant launch periods in the company's history across a diverse set of new therapeutic areas and modalities.

    "We are excited to expand our strategic partnership with Veeva by moving to Vault CRM," said Dave Williams, executive vice president and chief information and digital officer at Merck. "We share a deep commitment to customer success, and Vault CRM will provide Merck the technology foundation to drive commercial execution."

    "Merck has consistently been at the forefront of leading-edge science that improves the lives of millions around the world," said Veeva CEO Peter Gassner. "We are honored to be a strategic partner to Merck and it is great to see our partnership extend to Vault CRM."

    Vault CRM is part of the Vault CRM Suite of deep applications that drive more effective commercial execution across personal and digital channels. With advanced global capabilities, Vault CRM Suite addresses the industry's unique regional and country-specific business and compliance requirements. 

    About Veeva Systems

    Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

    Contact:

     



    Maria Scurry

    Veeva Systems

    [email protected]

    Meera Lakhani-Patel

    Veeva Europe

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/merck-commits-to-veeva-vault-crm-302509227.html

    SOURCE Veeva Systems

    Get the next $MRK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRK
    $VEEV

    CompanyDatePrice TargetRatingAnalyst
    Veeva Systems Inc.
    $VEEV
    5/29/2025$270.00 → $300.00Buy
    Needham
    Merck & Company Inc.
    $MRK
    5/14/2025$84.00Buy → Neutral
    Citigroup
    Merck & Company Inc.
    $MRK
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    Merck & Company Inc.
    $MRK
    2/18/2025$128.00 → $105.00Buy → Hold
    Deutsche Bank
    Merck & Company Inc.
    $MRK
    2/10/2025$121.00 → $100.00Buy → Hold
    TD Cowen
    Veeva Systems Inc.
    $VEEV
    1/23/2025$261.00 → $200.00Buy → Sell
    Goldman
    Merck & Company Inc.
    $MRK
    1/8/2025$110.00Buy → Hold
    Truist
    Veeva Systems Inc.
    $VEEV
    12/20/2024$280.00Overweight
    Stephens
    More analyst ratings

    $MRK
    $VEEV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

    Global partnerships to help customers improve clinical and commercial efficiency and effectiveness IQVIA (NYSE:IQV) and Veeva Systems (NYSE:VEEV) today announced global clinical and commercial partnerships and the complete resolution of all pending legal disputes. Under the terms of the long-term agreement, customers can use software, data, technology, and service offerings from Veeva and IQVIA together in a simple and efficient way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250818883712/en/ The global partnerships make it easy for customers to work with IQVIA and Veeva in key areas including: Commercial: The companies

    8/18/25 9:00:00 AM ET
    $IQV
    $VEEV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

    Data from IDeate-Lung01 trial will be presented at upcoming IASLC 2025 World Conference on Lung Cancer First Breakthrough Therapy Designation for Daiichi Sankyo and Merck's ifinatamab deruxtecan based on IDeate-Lung01 phase 2 trial, with support from IDeate-PanTumor01 phase 1/2 trial Fourteenth Breakthrough Therapy Designation granted by FDA across the oncology portfolio of Daiichi Sankyo Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. Ifinatamab derux

    8/18/25 7:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as Monotherapy

    Approval is based on KEYNOTE-689 Phase III Clinical Trial Results KIRKLAND, QC, Aug. 13, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 (Combined Positive Score [CPS] ≥ 1), as determined by a validated test, as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy.

    8/13/25 7:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    $VEEV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Veeva Systems with a new price target

    Needham reiterated coverage of Veeva Systems with a rating of Buy and set a new price target of $300.00 from $270.00 previously

    5/29/25 7:48:02 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Merck downgraded by Citigroup with a new price target

    Citigroup downgraded Merck from Buy to Neutral and set a new price target of $84.00

    5/14/25 8:57:17 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Merck with a new price target

    Cantor Fitzgerald initiated coverage of Merck with a rating of Neutral and set a new price target of $85.00

    4/22/25 8:01:38 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    $VEEV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    $VEEV
    SEC Filings

    View All

    $MRK
    $VEEV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Veeva Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - VEEVA SYSTEMS INC (0001393052) (Filer)

    8/18/25 9:06:47 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    SEC Form 13F-HR filed by Merck & Company Inc.

    13F-HR - Merck & Co., Inc. (0000310158) (Filer)

    8/13/25 5:05:55 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Merck & Company Inc.

    10-Q - Merck & Co., Inc. (0000310158) (Filer)

    8/5/25 4:13:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Chief Info&Digital Officer Williams David Michael exercised 17,119 shares at a strike of $79.29 and covered exercise/tax liability with 8,432 shares, increasing direct ownership by 36% to 33,013 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    8/5/25 8:46:15 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Marketing Officer Guindo Chirfi exercised 36,903 shares at a strike of $79.29 and covered exercise/tax liability with 18,175 shares, increasing direct ownership by 27% to 89,234 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    8/5/25 8:43:24 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Gen. Counsel, Secretary Faddis Jonathan sold $205,646 worth of shares (720 units at $285.62), decreasing direct ownership by 8% to 7,902 units (SEC Form 4)

    4 - VEEVA SYSTEMS INC (0001393052) (Issuer)

    7/11/25 5:27:16 PM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    $MRK
    $VEEV
    Leadership Updates

    Live Leadership Updates

    View All

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

    WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023.  Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India. As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annua

    11/14/23 5:25:00 PM ET
    $ASH
    $MRK
    Specialty Chemicals
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    $VEEV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Veeva Systems Inc. (Amendment)

    SC 13G/A - VEEVA SYSTEMS INC (0001393052) (Subject)

    2/16/24 4:29:43 PM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Veeva Systems Inc. (Amendment)

    SC 13G/A - VEEVA SYSTEMS INC (0001393052) (Subject)

    2/14/24 3:12:28 PM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Veeva Systems Inc. (Amendment)

    SC 13G/A - VEEVA SYSTEMS INC (0001393052) (Subject)

    2/14/24 10:03:02 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    $MRK
    $VEEV
    Financials

    Live finance-specific insights

    View All

    Veeva to Release Fiscal 2026 Second Quarter Results on August 27, 2025

    PLEASANTON, Calif., Aug. 6, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) will announce financial results for its second quarter, which ended July 31, 2025, after market close on August 27, 2025. Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET) to discuss its financial results. Veeva will post prepared remarks to its investor relations website at https://ir.veeva.com at approximately 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available on the website following the live event. Event: Veeva Systems' Fiscal 2026 Second Quarter Results Conference Call Date: Wednesday, August 27, 2025 Time: 2:00 p.m. PT (5:00 p.m. ET) Conference Call Registrati

    8/6/25 4:05:00 PM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results

    Total Worldwide Sales Were $15.8 Billion, a Decrease of 2% From Second Quarter 2024 Both Nominally and Excluding the Impact of Foreign Exchange KEYTRUDA Sales Were $8.0 Billion, Growth of 9% Both Nominally and Excluding the Impact of Foreign Exchange WINREVAIR Sales Were $336 Million Animal Health Sales Were $1.6 Billion, Growth of 11% Both Nominally and Excluding the Impact of Foreign Exchange GARDASIL/GARDASIL 9 Sales Were $1.1 Billion, a Decline of 55% Both Nominally and Excluding the Impact of Foreign Exchange GAAP EPS Was $1.76; Non-GAAP EPS Was $2.13; GAAP and Non-GAAP EPS Include a Charge of $0.07 per Share for Closing of Hengrui Pharma License Agreement Announce

    7/29/25 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Announces Fourth-Quarter 2025 Dividend

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the fourth quarter of 2025. Payment will be made on Oct. 7, 2025 to shareholders of record at the close of business on Sept. 15, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten

    7/22/25 11:53:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care